Javascript must be enabled to continue!
Micronuclei and Nuclear Abnormalities Observed in Erythroblasts in Myelodysplastic Syndromes and in de novo Acute Leukemia after Treatment
View through CrossRef
The frequencies of erythroblasts with micronuclei (EBM) and erythroblasts with aberrant nuclear shapes (EBAN) in bone marrow were evaluated in 60 patients with untreated myelodysplastic syndrome (MDS), and also in 21 patients with acute leukemia before and after treatment, and the results were compared regarding cytogenetic patterns. In patients with acute leukemia, the frequencies of EBM and EBAN in bone marrow were 0.60 ± 0.35% (mean ± SD) and 1.2 ± 1.1% before treatment, respectively, the former of which was higher than those obtained from 93 patients with various nonmalignant diseases (p < 0.01). After treatment with antileukemic drugs, the mean values of them significantly increased 9.7 and 6.1 times from the pretreatment ones, respectively. No correlation was found between the yields of EBM and EBAN and cytogenetic patterns, although regimens including administration of vincristine seemed to cause them more frequently. Most patients with MDS showed a consistent increase of EBM and EBAN at the time of diagnosis irrespective of the treatment; the mean frequencies were 7.7 and 6.3 times higher than those obtained from patients with nonmalignant diseases, respectively. Furthermore, the numbers of EBM and EBAN were significantly higher in patients with an abnormal karyotype than those with a normal karyotype (p < 0.05 for EBM and p < 0.001 for EBAN). In particular, 8 patients with a monosomy 7q showed a marked increase of EBAN (4.7 ± 4.4%) and EBAN (13 ± 6.5%). These findings revealed that drastic changes in the morphology of erythroblasts were characteristic features of MDS, and may reflect a disturbance in kinetochore/spindle microtubules, such as endoreduplication, c-mitosis or restitution, in addition to chromosome lagging.
Title: Micronuclei and Nuclear Abnormalities Observed in Erythroblasts in Myelodysplastic Syndromes and in de novo Acute Leukemia after Treatment
Description:
The frequencies of erythroblasts with micronuclei (EBM) and erythroblasts with aberrant nuclear shapes (EBAN) in bone marrow were evaluated in 60 patients with untreated myelodysplastic syndrome (MDS), and also in 21 patients with acute leukemia before and after treatment, and the results were compared regarding cytogenetic patterns.
In patients with acute leukemia, the frequencies of EBM and EBAN in bone marrow were 0.
60 ± 0.
35% (mean ± SD) and 1.
2 ± 1.
1% before treatment, respectively, the former of which was higher than those obtained from 93 patients with various nonmalignant diseases (p < 0.
01).
After treatment with antileukemic drugs, the mean values of them significantly increased 9.
7 and 6.
1 times from the pretreatment ones, respectively.
No correlation was found between the yields of EBM and EBAN and cytogenetic patterns, although regimens including administration of vincristine seemed to cause them more frequently.
Most patients with MDS showed a consistent increase of EBM and EBAN at the time of diagnosis irrespective of the treatment; the mean frequencies were 7.
7 and 6.
3 times higher than those obtained from patients with nonmalignant diseases, respectively.
Furthermore, the numbers of EBM and EBAN were significantly higher in patients with an abnormal karyotype than those with a normal karyotype (p < 0.
05 for EBM and p < 0.
001 for EBAN).
In particular, 8 patients with a monosomy 7q showed a marked increase of EBAN (4.
7 ± 4.
4%) and EBAN (13 ± 6.
5%).
These findings revealed that drastic changes in the morphology of erythroblasts were characteristic features of MDS, and may reflect a disturbance in kinetochore/spindle microtubules, such as endoreduplication, c-mitosis or restitution, in addition to chromosome lagging.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
miRNA-144/451 Regulates Cell Surface TfR1 Expression in Normal and β-Thalassemic Erythroblasts
miRNA-144/451 Regulates Cell Surface TfR1 Expression in Normal and β-Thalassemic Erythroblasts
β-thalassemia is a common inherited blood disorder caused by mutations in the β-globin gene (HBB) leading to a reduction of the corresponding protein. Consequently, excess free α-g...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract
Abstract 1606
Introduction:
Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
Abstract 132: African polyherbal formulation alleviates benzene-induced leukemia in Wistar rats
Abstract 132: African polyherbal formulation alleviates benzene-induced leukemia in Wistar rats
Abstract
Background: Chemotherapy and radiotherapy are effective cancer treatment options but they are accompanied by serious side effects. Therefore, more effective...
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical...
MYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES
Introduction: Myelodysplastic syndrome is a pathology characterized by its hematopoietic, pluripotential ineffective process in the bone marrow, i.e. causing dysplasia in at least ...
The Location of Genomic Breakpoints in AML1/RUNX1 and ETO in De Novo znd Therapy-Related Leukemia Patients sith T(8;21) Are Similar znd Colocalize with Topoisomerase II Cleavage Sites.
The Location of Genomic Breakpoints in AML1/RUNX1 and ETO in De Novo znd Therapy-Related Leukemia Patients sith T(8;21) Are Similar znd Colocalize with Topoisomerase II Cleavage Sites.
Abstract
The t(8;21)(q22;q22) that results in an AML1-ETO fusion gene is frequently detected in de novo and in therapy-related acute myeloid leukemia (AML) patients....

